Will My Insurance Cover Semaglutide for Weight Loss?

Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Possibly, and the first thing to establish is not your body mass index but whether your plan covers anti-obesity medications as a benefit category at all. Many plans exclude them outright, which is a benefit-design decision rather than a clinical one and cannot be appealed on clinical grounds. The second thing to establish is which product is being requested: Wegovy carries the weight-management indications, while Ozempic is approved only for type 2 diabetes. Plans key coverage to the indication, not the molecule.

Ask the Exclusion Question First

One written question to your plan resolves more than any amount of documentation: are anti-obesity medications an excluded benefit under this specific policy? Request the relevant page of the plan document rather than accepting a verbal answer.

If the answer is yes, clinical criteria never come into play. The realistic routes are an employer-level formulary change, a different plan at open enrollment, or a cash-pay path. Assembling a prior authorization file against an exclusion wastes weeks that a single phone call would have saved.

If the answer is no, you are in a medical-necessity conversation, which is appealable and frequently winnable.

Match the Request to a Labeled Indication

Wegovy injection carries three indications: reduction of major adverse cardiovascular event risk in adults with established cardiovascular disease and either obesity or overweight; long-term weight reduction in adults and pediatric patients aged 12 and older with obesity and in adults with overweight plus at least one weight-related comorbid condition; and noncirrhotic MASH with moderate to advanced liver fibrosis under accelerated approval.

Those are three different requests with three different documentation profiles. The cardiovascular indication in particular sometimes falls outside a plan’s anti-obesity exclusion, because it is not a weight-reduction indication.

Wegovy tablets carry the adult cardiovascular risk reduction and weight reduction indications only. If a plan’s formulary favours oral therapy, that is worth knowing before the request is written.

What Prior Authorization Criteria Usually Require

Common requirements include documented body mass index consistent with the labeled population, documented weight-related comorbid conditions, evidence of a prior structured attempt at diet and physical activity, and in many plans a trial of a preferred alternative agent first. The specific thresholds are set by the payer, not by the FDA.

For reference, the pivotal trials used body mass index of 30 kg/m² or greater for obesity and 27 to 29.9 kg/m² with at least one weight-related comorbid condition such as treated or untreated dyslipidemia or hypertension.

Continued authorization increasingly requires documented follow-up and demonstrated response, which aligns with the label’s own direction that treatment response and tolerability be considered when selecting a maintenance dosage.

Building the File Your Prescriber Submits

The submission is only as strong as the chart. Useful documentation includes measured height and weight with dates, calculated body mass index, diagnosis codes for every weight-related condition, records of prior interventions and their outcomes, and any relevant laboratory results.

If you have established cardiovascular disease, or a MASH diagnosis, or are a pediatric patient aged 12 or older with obesity, make sure that appears explicitly rather than being implied. Those map to distinct indications, and a reviewer works from what is written.

When a Denial Arrives

Read it for the stated reason and the deadline, both of which are always present. Denials for missing documentation are the easiest to reverse. Denials for failure to meet clinical criteria turn on whether the chart supports the criteria as written. Denials for a non-covered benefit category are the hardest and usually terminal.

Most plans provide an internal appeal followed by external review by an independent review organisation. A peer-to-peer discussion between your prescriber and the plan’s medical director is often the fastest lever on a clinical-criteria denial. Keep every reference number and date, because appeal windows are strict.

If Coverage Is Not Available

Manufacturer savings and direct-purchase programs operate outside the insurance channel with their own eligibility rules, which change frequently enough that they should be verified directly with the manufacturer rather than from any secondary summary.

Compounded semaglutide is a separate cash-pay category rather than a covered alternative. The FDA states that compounded drugs are not FDA-approved, that it does not verify their safety, effectiveness or quality before marketing, and that compounded drugs are not the same as generic drugs, which must establish therapeutic equivalence under section 505(j). There is no approved generic semaglutide.

Whichever route you take, plan for the long horizon. Randomised withdrawal trials in this class consistently show substantial weight regain after discontinuation, and coverage that lapses mid-course produces exactly that outcome.

Timing and the Plan Year

Coverage in this category is unusually volatile between plan years, because sponsors are actively reassessing anti-obesity benefits against utilisation. A policy that excluded the category last year may not this year, and the reverse happens just as often.

That makes two moments worth marking. Open enrollment is when a benefit design can actually be chosen rather than appealed, and it is the only reliable lever against a categorical exclusion short of an employer-level change. And the start of each plan year is when prior authorizations commonly need to be renewed, which is a frequent and avoidable cause of an interruption in therapy.

Interruptions matter clinically, not just administratively. Randomised withdrawal trials in this class consistently show substantial weight regain after discontinuation, and a coverage lapse produces the same physiology as a decision to stop.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What is the single most useful question to ask my insurer?

Whether anti-obesity medications are an excluded benefit under your specific policy, asked in writing with a request for the relevant page of the plan document. That one question distinguishes a benefit exclusion, which clinical documentation cannot overcome and which is generally not appealable on clinical grounds, from a medical-necessity denial, which is appealable and frequently winnable.

Does asking for Ozempic instead help?

No, and it usually hurts. Ozempic is approved only for type 2 diabetes indications and has no weight-management indication, so a weight-based request for it falls outside the label. Plans key coverage to the approved indication rather than the molecule. Wegovy carries the weight-management indications and is the product a weight-based request should name.

What documentation do plans typically require?

Measured height and weight with dates, calculated body mass index consistent with the labeled population, diagnosis codes for weight-related comorbid conditions, and evidence of a prior structured attempt at diet and physical activity. Many plans also require a trial of a preferred alternative first and documentation of ongoing follow-up and response for continued authorization.

Can a cardiovascular diagnosis change the outcome?

It can, because Wegovy injection carries a separate indication for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. That is not a weight-reduction indication, and some plans treat it differently from their anti-obesity exclusion. Have your prescriber document it explicitly rather than by implication.

Is compounded semaglutide a covered alternative?

Generally not. Compounded preparations are not FDA-approved finished products, the agency does not verify their safety, effectiveness or quality before marketing, and the FDA distinguishes them from generic drugs, which must establish therapeutic equivalence under section 505(j). There is no approved generic semaglutide, so they sit outside the formulary structure that coverage runs through.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.